HER-Vaxx induced antibodies correlated with tumour reduction
Filed with ASX · · 3 pages · English
presented at the World Congress of Gastrointestinal Cancer in Barcelona. Abstract Title: HERIZON: A Phase 2 study of HER-Vaxx (IMU-131), a HER-2-targeting peptide vaccine plus SOC chemotherapy in patients with HER-2+ advanced stomach Cancer — Correlation of the antibody responses and clinical outcome. Session Title: Basic Gastric Cancer – Biomarkers and Translational Research. Session Number: Post
Earlier from Imugene
- Imugene PD1-Vaxx patent extended to 2040
- Imugene Advances VAXINIA MAST Trial to Next IV Cohorts
- Imugene doses first combination patient in PD1-Vaxx trial
- Imugene secures IND approval for first-in-class onCARlytics trial
- FDA clears Imugene IND for onCARlytics first-in-class study
Later from Imugene
- New Dose Escalation in Phase I Clinical Trial of CHECKvacc
- Imugene Oncolytic Virotherapy CF33 Patent Allowed in the US
- Imugene and RenovoRx CF33 Virotherapy Delivery Collaboration
- Imugene HER-Vaxx and CHECKVacc to be Featured at ESMO
- Imugene CF33 Oncolytic Virus Study to be Showcased at SITC
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene